Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)

Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)

Pexastimogene devacirepvec (Pexa-Vec) is a vaccinia virus-based oncolytic immunotherapy designed to preferentially replicate in and destroy tumor cells while stimulating anti-tumor immunity by expressing GM-CSF. An earlier randomized Phase IIa trial in predominantly sorafenib-naïve hepatocellular ca...

Full description

Bibliographic Details
Main Authors: M. Moehler, J. Heo, H.C. Lee, W.Y. Tak, Y. Chao, S.W. Paik, H.J. Yim, K.S. Byun, A. Baron, G. Ungerechts, D. Jonker, L. Ruo, M. Cho, A. Kaubisch, H. Wege, P. Merle, O. Ebert, F. Habersetzer, J.F. Blanc, Olivier Rosmorduc, R. Lencioni, R. Patt, A.M. Leen, F. Foerster, M. Homerin, N. Stojkowitz, M. Lusky, J.M. Limacher, M. Hennequi, N. Gaspar, B. McFadden, N. De Silva, D. Shen, A. Pelusio, D.H. Kirn, C.J. Breitbach, J.M. Burke
Format: Article
Language:English
Published: Taylor & Francis Group 2019-08-01
Series:OncoImmunology
Subjects:
hepatocellular carcinoma
pexa-vec
sorafenib
oncolytic immunotherapy
oncolytic vaccinia
Online Access:http://dx.doi.org/10.1080/2162402X.2019.1615817

Internet

http://dx.doi.org/10.1080/2162402X.2019.1615817

Similar Items